Related Experiment Video
Updated: Sep 9, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
AMSC/CXCR4-derived exosomes and miRNA-320 regulate pathological angiogenesis in diabetes
Shenhao Wu1, Xiaomei Luo2, Yanwen Liu1
1The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, China.
Background:
Diabetic vascular complications present significant clinical challenges, including limited treatment efficacy, high postoperative restenosis rates, and delayed early diagnosis. This study investigates CXCR4-modified adipose-derived mesenchymal stem cells (AMSCs/CXCR4) in regulating pathological endothelial proliferation under hyperglycemic conditions.
Aims:
The purpose is to provide new mechanism insights and potential therapeutic targets for early intervention of diabetes-related vascular diseases.
Methods:
The CXCR4-overexpressing plasmid was generated via XhoI/EcoRI double digestion, T4 ligation, and column purification, then transfected into AMSCs using Lipofectamine® 3000 to enhance exosome secretion. These exosomes were co-cultured with HG-treated HUVECs. Cell viability and apoptosis were assessed by CCK8 and flow cytometry. AKT/mTOR pathway proteins (total/phosphorylated) were analyzed via Western blot, while qRT-PCR quantified miRNA320, VEGF, and IGF-1 expression.
Results:
Chronic high glucose stimulated abnormal endothelial cell proliferation (CCK-8/flow cytometry), which was suppressed by AMSCs/CXCR4, reducing proliferation and elevating apoptosis ( 21.723 ± 1.061% apoptosis rate)). High glucose downregulated miRNA320, but AMSCs/CXCR4 restored its expression ( 0.937 ± 0.056 vs. other groups, P < 0.05). Increased miRNA320 correlated with reduced VEGF ((1.101 ± 0.142) and IGF-1 (1.074 ± 0.084) levels, confirming miRNA320-mediated inhibition. Notably, activation of the AKT/mTOR pathway proteins was not affected, indicating that AMSCs/CXCR4 directly inhibited the activity of VEGF and IGF-1 in HUVECs via miRNA320.
Conclusions:
CXCR4 boosts exosome release from AMSCs. Although AMSCs/CXCR4 did not alter AKT/mTOR signaling, their miRNA320-loaded exosomes blocked IGF-1/VEGF activity. This study uncovers a CXCR4-miRNA320 axis in diabetic vascular dysfunction, highlighting exosome-based therapy and miRNA320 as a targeted strategy for vascular complications.
Insights
CXCR4-modified stem cells release exosomes that reduce abnormal blood vessel growth in diabetes by increasing miRNA320, offering a new therapy for diabetic vascular complications.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Molecular Biology
Background:
- Diabetic vascular complications pose significant challenges due to limited treatment efficacy and high restenosis rates.
- Pathological endothelial proliferation under hyperglycemia contributes to these complications.
- Adipose-derived mesenchymal stem cells (AMSCs) modified with CXCR4 (AMSCs/CXCR4) are investigated for their therapeutic potential.
Purpose of the Study:
- To elucidate the mechanisms by which AMSCs/CXCR4 regulate endothelial proliferation in diabetes.
- To identify novel therapeutic targets for early intervention in diabetes-related vascular diseases.
- To explore the role of exosomes secreted by AMSCs/CXCR4.
Main Methods:
- Generation of CXCR4-overexpressing plasmid and transfection into AMSCs to enhance exosome secretion.
- Co-culture of exosomes with high glucose-treated human umbilical vein endothelial cells (HUVECs).
- Assessment of cell viability, apoptosis, Western blot analysis of AKT/mTOR pathway, and qRT-PCR for miRNA320, VEGF, and IGF-1 expression.
Main Results:
- AMSCs/CXCR4 exosomes suppressed high glucose-induced endothelial cell proliferation and increased apoptosis.
- High glucose downregulated miRNA320, which was restored by AMSCs/CXCR4 exosomes.
- Restored miRNA320 inhibited VEGF and IGF-1 expression, independent of the AKT/mTOR pathway.
Conclusions:
- CXCR4 enhances exosome release from AMSCs, delivering therapeutic cargo.
- AMSCs/CXCR4-derived exosomes, via miRNA320, inhibit IGF-1/VEGF activity, independent of AKT/mTOR signaling.
- A CXCR4-miRNA320 axis is identified in diabetic vascular dysfunction, suggesting exosome-based therapy and miRNA320 as promising strategies.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
01:19Mesenchymal Stem Cells